Pharmaceuticals

Silo Pharma has navigated a critical headwind, regaining Nasdaq compliance. This move provides vital stability, allowing the firm to focus on its true test.

Scienture Holdings' Arbli™ just gained 12.5M covered lives. It's not about the $219M market, but the overlooked patients who can't swallow pills.

A new partnership between Charles River and Lilly TuneLab merges AI with nonclinical testing, aiming to fast-track new medicines and level the field for biotechs.

A new firm, Nortiva Bio, is launching with tech from MIT to turn daily pills into monthly doses, starting with a contraceptive backed by the Gates Foundation.

A new drug from Cambrian Bio shows promise in activating a key metabolic switch. This could lead to treatments that burn fat while preserving muscle mass.

A new grant from The Michael J. Fox Foundation highlights a radical approach to Parkinson's: targeting astrocytes to restore balance and halt neurodegeneration.

A court ruling clears the way for Curium's targeted cancer drug, promising new hope for patients and shaking up the multi-billion-dollar radiopharmaceutical market.

With a key webinar ahead, Arrowhead Pharma is showcasing a trio of gene-silencing drugs. Can its TRiM™ platform upend a multi-billion dollar cardiometabolic market?

With enhanced GMP cell banking suites, Minaris integrates manufacturing and testing in Philadelphia, aiming to accelerate development in the booming CGT market.

With a fresh $50M, Enhanced Group is selling a future of medically-guided peak performance. But can its controversial Games and peptide platform survive regulatory scrutiny?

A new patent gives CervoMed a long runway for its dementia drug, but can this IP victory secure the massive funding needed to cross the finish line?

Asimov's AI-driven synthetic biology platform partners with McGill's Goodman Cancer Institute, aiming to break the manufacturing bottleneck for complex drugs.

Memo Therapeutics' Potravitug shows promise in a Phase II trial, offering the first real weapon against a common virus that threatens kidney transplants.

RedHill Biopharma's new financing provides crucial cash, but the real story is in the warrants and the hunt for a strategic acquisition. A deep dive.

A 'dream team' of pharma veterans has raised $180M to advance a next-gen oral drug, promising to transform the multi-billion dollar IBD market.

As CFO Dave Denton departs for the consumer goods sector, Pfizer taps a 20-year veteran for the interim role, signaling continuity amid a crucial post-acquisition phase.

Merck secures a pivotal FDA approval for its CAPVAXIVE vaccine, offering new hope for at-risk youth and challenging rivals in the high-stakes pneumococcal market.

A Taipei delegation at BIO 2026 signals Taiwan's strategic pivot from manufacturing to R&D, seeking global partners for its late-stage drugs and platforms.

At BIO 2026, Transpire Bio isn't just presenting; it's pitching a new paradigm for medicine, using inhalation to tackle everything from diabetes to cancer.

German biotech Mallia Aesthetics reports impressive results for its hormone-free hair serum, but the real story lies in its resilient, science-first strategy.